Acute Pulmonary Embolism, APE
Conditions
Interventions
Index test:New molecular markers of thrombosis: thrombin-antithrombin III complex (TAT), plasmin -a2 plasmin inhibitor complex (PIC), thrombomodulin (TM), tissue plasminogen activator inhibitor 1 comp
Sponsors
Beijing Anzhen Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with APE for the first time through CTPA in clinical practice and who have not received anticoagulant therapy in the past month; 2.Age >= 18 years old.
Exclusion criteria
Exclusion criteria: Exclusion criteria for APE patients: 1. Excluding patients with other thrombotic diseases, complicated with important injuries of heart, liver, kidney and other organs, previous history of pulmonary embolism, and use of anticoagulant or thrombolytic drugs within one month; 2. Malignant tumors; 3. Renal dialysis patients; 4. Antiphospholipid syndrome; 5. Immune system diseases; 6. Hematological diseases; 7. DIC caused by severe infection; 8. Patients judged by clinicians to be unfit for clinical practice.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombin-antithrombin III complex, TAT;Plasmin -a2 plasmin inhibitor complex, PIC;Thrombomodulin, TM;Tissue plasminogen activator-inhibitor 1 complex, t-PAIC;Activated partial thromboplastin time, APTT;Fibrinogen, FIB;D-dimer;Fibrin (fibrinogen) degradation products, FDP; | — |
Countries
China
Contacts
Public ContactZhang Lei
Beijing Anzhen Hospital Affiliated to Capital Medical University
Outcome results
None listed